PRESS-RELEASE ·Filed Apr 29, 2026
Press release: contract
Actionable Insight • Neutral
This is a non-material marketing campaign with no disclosed financial impact. No immediate trading catalyst.
Final — all horizons settled through T+60d ⚠ clustered
EBS ▼ -9.14% at T+60d
NEUTRAL call ✗ call lost -9.14% · α vs SPY -13.25% · entry $7.99 → $7.26
T+1d
+3.00%
call +3.00% · α +1.98%
$8.23
settled 5mo ago
T+5d
+13.89%
call +13.89% · α +10.78%
$9.10
settled 5mo ago
T+20d
+14.89%
call +14.89% · α +8.85%
$9.18
settled 4mo ago
T+60d
-9.14%
call -9.14% · α -13.25%
$7.26
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Emergent BioSolutions announced a partnership with baseball player Davis Schneider to promote awareness of NARCAN Nasal Spray for opioid overdose reversal. The campaign includes an interactive Opioid Crisis Impact Map and aims to reduce stigma. No financial terms were disclosed.
Key Facts
- Partnership with Toronto Blue Jays' Davis Schneider to promote NARCAN Nasal Spray
- Schneider shares his personal story of losing his brother to opioid overdose on Emergent's Opioid Crisis Impact Map
- More than 100 million doses of NARCAN Nasal Spray delivered since 2018
- NARCAN Nasal Spray available at no cost in several Canadian provinces and territories
Financial Impact
No financial terms disclosed; campaign is primarily educational and awareness-focused.
Risk Factors
- No discernible risk from this announcement
Market Snapshot
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283594 |
16 reports for EBS
60% Hit rate best @ T+20▲ +14.89%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | Press Release | $4.45 $5.68 | ▼ −27.64% | ▼ −28.70% | $6.29 (−41.35%) |
Jun 29, 2026 13w ago | 8-K | $8.46 $7.26 | ▼ −14.18% | ▼ −13.90% | $6.29 (−25.65%) |
Jun 4, 2026 17w ago | Press Release | $8.44 $8.28 | ▼ −1.90% | ▼ −0.52% | $6.29 (−25.47%) |
Apr 30, 2026 22w ago | Press Release | $8.47 $8.49 | ▲ +0.24% | ▼ −5.05% | $6.29 (−25.74%) |
Apr 30, 2026 22w ago | Insider Cluster | $8.23 $9.18 | ▲ +11.54% | ▲ +6.58% | $6.29 (−23.57%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 28, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 28, 2026 22w ago | Press Release | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 27, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Showing 10 of 16
US Market Status
Market Open — Closes in 2h 17m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access